- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05257746
Perioperative and Postoperative Evaluation of Rectal and Urogenital Function in Patients Undergoing Rectal Resection (PERIFUNC)
August 25, 2026 updated by: Technische Universität Dresden
The aim of this study is the systematic analysis of the development of perioperative rectal and urogenital function in patients undergoing rectal resection with total mesorectal excision and the identification of risk factors for urogenital and sphincter function loss after this procedure.
Knowledge of the corresponding risk factors could enable the identification of patient cohorts that could benefit from an intensified or altered postoperative treatment path.
The results of this study could thus significantly influence the clinical management of patients with rectal cancer and improve the functional outcome in the long term.
Study Overview
Study Type
Observational
Enrollment (Estimated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Johannes Fritzmann, Dr.
- Phone Number: +49 351 458 19477
- Email: johannes.fritzmann@ukdd.de
Study Locations
-
-
Saxony
-
Dresden, Saxony, Germany, 01307
- Recruiting
- Department of Gastrointestinal-, Thoracic and Vascular Surgery University Hospital Carl Gustav Carus Technische Universität Dresden
-
Contact:
- Johannes Fritzmann, Dr.
- Phone Number: +49 351 458 19477
- Email: johannes.fritzmann@ukdd.de
-
Sub-Investigator:
- Fiona Kolbinger, Dr.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
All patients undergoing rectal resection with total mesorectal excision
Description
Inclusion Criteria:
- Patients undergoing rectal resection with total mesorectal excision
Exclusion Criteria:
- primary or secondary removal of rectal sphincter apparatus
- patients with enterostomy persisting 12 months after initial rectal resection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assessment of pelvic function before and after rectal resection
Time Frame: 5 years
|
Rectal and urogenital function will be assessed preoperatively and 12-24 months and 5 years postoperatively using the PERIFUNC score questionnaire, resulting in a score between 0 and 120.
Higher scores mean a worse outcome (worse pelvic function).
|
5 years
|
|
Rectal sphincter function before and after rectal resection
Time Frame: 5 years
|
Sphincter function will be assessed by manometry preoperatively and 12 - 24 months and 5 years postoperatively
|
5 years
|
|
Assessment of stool continence before and after rectal resection
Time Frame: 5 years
|
Stool continence will be assessed preoperatively and 12-24 months and 5 years postoperatively using the LARS score questionnaire, resulting in a score between 0 and 42.
Higher scores mean a worse outcome (worse stool continence).
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of postoperative hospital stay [days]
Time Frame: At day of discharge, assessed up to 90 days
|
Postoperative day 1 until day of discharge
|
At day of discharge, assessed up to 90 days
|
|
Duration of postoperative intermediate/intensive care unit stay [days]
Time Frame: At day of discharge, assessed up to 90 days
|
Postoperative day 1 until day of discharge
|
At day of discharge, assessed up to 90 days
|
|
Operating time [min]
Time Frame: during surgery
|
Time from skin incision until placement of last skin staple/suture.
|
during surgery
|
|
Intraoperative blood loss [mL]
Time Frame: during surgery
|
Intraoperative blood loss presents the amount of blood lost from skin incision until skin closure.
Spilling water and ascites will be subtracted.
Swabs will be squeezed and their content will also be sucked and added to the fluid collected in the suction containers
|
during surgery
|
|
Frequency of peri-operative morbidity after resection
Time Frame: 90 days after surgery
|
Frequency of peri-operative complications after resection
|
90 days after surgery
|
|
Kind of peri-operative morbidity after resection
Time Frame: 90 days after surgery
|
Kind of peri-operative complications after resection
|
90 days after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Johannes Fritzmann, Dr., Technische Universität Dresden
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 3, 2021
Primary Completion (Estimated)
June 30, 2030
Study Completion (Estimated)
June 30, 2030
Study Registration Dates
First Submitted
February 7, 2022
First Submitted That Met QC Criteria
February 24, 2022
First Posted (Actual)
February 25, 2022
Study Record Updates
Last Update Posted (Actual)
August 27, 2026
Last Update Submitted That Met QC Criteria
August 25, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VTG-10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Following publication of study results, de-identified patient data will be made available upon reasonable request
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.